Analysts forecast a 3% year-over-year earnings increase for Johnson & Johnson amid Stelara sales decline.
Johnson & Johnson is poised to report second-quarter earnings of $2.85 per share on July 15, reflecting a roughly 3% year-over-year increase. Analysts anticipate an upbeat print despite headwinds from declining Stelara sales, which now represent a smaller portion of revenue.
Wall Street consensus aligns with expectations for growth, driven by strong historical performance and raised guidance. The company’s oncology and neuroscience portfolios remain key growth drivers, offsetting challenges in its product mix.
Investor focus will likely center on the resilience of these high-growth segments as the firm navigates evolving market dynamics.